PT - JOURNAL ARTICLE AU - Ren, Zhenxiao AU - Furukawa, Koichi AU - Nishimura, Mitsuhiro AU - Kurahashi, Yukiya AU - Sutandhio, Silvia AU - Tjan, Lidya Handayani AU - Aoki, Kaito AU - Hasegawa, Natsumi AU - Arii, Jun AU - Uto, Kenichi AU - Matsui, Keiji AU - Sato, Itsuko AU - Saegusa, Jun AU - Godai, Nonoka AU - Takeshita, Kohei AU - Yamamoto, Masaki AU - Nagashima, Tatsuya AU - Mori, Yasuko TI - Large-scale seroepidemiologic surveillance of COVID-19 - Cross-sectional study in Hyogo prefecture of Japan in August, 2021 AID - 10.1101/2021.09.26.21264129 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.26.21264129 4099 - http://medrxiv.org/content/early/2021/09/28/2021.09.26.21264129.short 4100 - http://medrxiv.org/content/early/2021/09/28/2021.09.26.21264129.full AB - The situation of the COVID-19 pandemic in Japan is drastically changing in the 2nd year, 2021, due to the appearance of SARS-CoV-2 variants of concern and the roll-out of mass vaccination. In addition to PCR diagnosis, periodic seroepidemiologic surveillance is important to analyze the epidemic situation. In this study, we analyzed the rate of seropositivity for the SARS-CoV-2 N and S antigens in Hyogo prefecture, Japan in August 2021. Sera collected from people who received a health check-up in a clinic of the Hyogo Prefecture Health Promotion Association were subjected to analysis of reactivity to the SARS-CoV-2 N and S antigens by electrochemiluminescence immunoassay (ECLIA) and enzyme-linked immunosorbent assay (ELISA), respectively. For a total 1,000 sera, the positive rates to N and S antigens were 2.1% and 38.7%, respectively. The infectious rate estimated by serological analysis based on the presence of the anti-N antibody was 2.5-fold higher than the value reported based on PCR-based analysis, and it increased five-fold compared to the rate determined by our previous seroepidemiologic study in October, 2020. The anti-S positive rate was almost consistent with the vaccination rate in this area. The observed high anti-S antibody level in the seropositive population may indicate that the mass vaccination in Japan is being performed smoothly at this time point, although the infectious rate has also increased.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNo clinical trial in this manuscript.Funding StatementThis work was supported by Hyogo Prefectural Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethical committees of Kobe University Graduate School of Medicine (approval codes: B2156702). Hyogo Prefecture Health Promotion Association was also granted approval under the ethical committee of Kobe University Graduate School of Medicine. Information about this retrospective observational study was published on the website of Kobe University Hospital, along with the opportunity to opt out. To validate the ELISA, sera from COVID-19 patients and healthy volunteers were used under approval of the ethical committee of Kobe University Graduate School of Medicine (approval code B200200), and written informed consent was obtained from the donors.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThere is no available data referred to the manuscript.COVID-19Coronavirus disease 2019SARS-CoV-2Severe acute respiratory syndrome coronavirus 2ECLIAElectrochemiluminescence immunoassayELISAEnzyme-linked inmmunosorbent assayNNucleocapsidSSpikePBSphosphate buffered salineCOIcut-off indexABTS2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid